Backed by science, built for growth

We are addressing the $23,8B global aesthetic injectables market, which continues to grow at 11% CAGR. While synthetic hyaluronic acid fillers dominate today, regenerative solutions are gaining rapid traction - projected to grow by ~20% annually. We are targeting this fastest growing segment.

Patients and physicians are increasingly demanding natural alternatives - but there is no scalable regenerative injectable on the market. Introduction of our medical device is timely and will meet a market that continues to grow in double digits.

Injectables boast very high gross margins and are among the most resilient segments of healthcare, with steady performance even during economic downturns. The aesthetics industry is also highly active in strategic M&A, with large players seeking category-defining innovations like ours.

Linio Biotech’s advantages in introducing a revolutionary solution include:

• Over 15 years of groundbreaking research on adipose tissue and it’s regenerative properties

• Seasoned in-house experts in regulatory processes

• Core-technology commercialization has created rich real-world data on efficacy and safety, partly de-risking the development of the medical device

‍

We are building long-term value through groundbreaking regenerative technology and a clear global pathway.

• Proprietary regenerative technology with strong IP position with multi-billion-dollar potential

• Tience core technology product launched in Europe

• Clear US and EU regulatory pathway underway

• Scalable strategy via partnerships and licensing opportunities